Advertise on podcast: Ventured Growth with Hercules Capital

Share your thoughts with us! AI is changing how teams work, but Dan Zhang isn’t interested in using it just to make people 20% more productive. She’s thinking much bigger—about what becomes possible when AI can take on the work that used to be limited by time, resources, and bandwidth. On this episode of Ventured Growth, Catherine Jhung and Tyler Wu sit down with Dan, CFO and Chief Business Officer at ClickUp, to talk about how she’s helping build a truly AI-native organization. Dan shares what ClickUp has learned from rolling out AI across the business—including why simply adding AI to existing processes didn’t work, and why they ended up “firing” thousands of AI agents. She also gets into her own approach to AI. Despite coming from a non-technical background, Dan has built an AI workforce that can execute multiple projects in parallel, challenge her thinking, and even act as an extension of how she makes decisions. Topics include: Building and managing an AI workforceWhy ClickUp fired thousands of AI agentsMoving from individual automation to AI orchestrationCreating AI governance that actually worksWhere CFOs should focus their AI investmentsWhy knowing exactly what you want may be the most valuable skill in the AI eraAnd more… As CFO and Chief Business Officer at ClickUp, Dan Zhang leads finance, accounting, corporate development, HR, legal, and strategic initiatives. Her approach combines the agility and grit of startup leadership with the rigorous operational discipline of scaling up. She enjoys building teams of operators that accelerate growth to consistently deliver outcomes and financial results. Dan is helping lead the company’s AI efforts and rethink how teams use AI across the organization. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! At Fin, going all-in on AI wasn't a moonshot — it was a calculated bet that doing nothing was the greater risk. And steering the financial strategy behind that decision was CFO Dan Griggs. On this episode of Ventured Growth, Catherine Jhung sits down with Dan to explore how Fin transformed from a traditional SaaS help desk into one of the most talked-about AI-native platforms in enterprise software. With a career spanning Nestlé, RocketFuel and Sitecore, Dan brings a rare mix of operational depth and financial discipline to one of the boldest pivots in SaaS. Dan also talks about the decision to overhaul their entire pricing model at the risk of cannibalizing existing revenue, how he thinks about forecasting in an outcome-based world, and what the role of CFO looks like when the pace of change never slows down. Topics include: * Fin's all-in bet on AI and what it took to get there * Overhauling a pricing model mid-flight to outcome-based revenue * How Fin forecasts in a usage-driven, AI-native business * Resource allocation and the internal debate around hiring vs. automation * Why $250 million in debt financing made more sense than equity * What the CFO role looks like in a company transforming at speed * And more... Dan Griggs is the CFO of Fin, where he leads financial planning and analysis, and accounting, drawing on more than 15 years in financial and leadership roles across high-growth technology companies. He previously served as CFO at Sitecore, where he helped transition the business to subscription-based cloud software while doubling revenue, and as VP of Financial Planning and Analysis at Rocket Fuel, where he drove over $400M in revenue growth and a successful IPO.   Intercom rebranded to Fin on May 12, 2026. This conversation took place prior to the rebrand, so the episode refers to the company as Intercom throughout. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! At Akcea Therapeutics, biotech leadership meant more than drug development—it meant building with purpose, addressing long-overlooked areas of health, and paving the way for future leaders. And at the helm was founding CEO Paula Soteropoulos. On this episode of Ventured Growth, Katie Segien sits down with Paula to explore how she helped take Akcea public, launched therapies for underserved diseases, and advanced efforts in women’s health—a space historically underfunded and under-researched. With 35 years of experience across pharma and biotech, Paula shares how she's using her platform to drive both innovation and inclusion. She also talks about mentoring the next generation of women CEOs, shaping boardroom dynamics, and why genomic medicine could help close longstanding gaps in women’s care. Topics include: Leading Akcea through IPO and pivotal drug launchesThe massive underfunding of research into women’s health Mentoring and elevating women in biotech leadershipBuilding purpose-driven executive teamsWhat’s next in in vivo genomic medicineAnd more… Paula Soteropoulos is a seasoned biotech executive, board member and advisor whose career spans a broad range of therapeutic areas, including rare disease, cardiovascular and metabolism, infectious disease, renal, and transplant and oncology. Paula is a Venture Partner at 5AM Ventures, and serves as Chairman of Ensoma, and on the boards of directors of Dianthus Therapeutics, Rallybio, and Kyowa Kirin. Paula was the founding CEO of rare disease therapeutic developer, Akcea Therapeutics, and was a board director at UniQure. She serves on the advisory boards for Chiesi USA and Tufts University Department of Chemical and Biological Engineering. Paula continues to lead and advise companies at the intersection of science, leadership, and women’s health.  This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! At Eight Sleep, product innovation isn’t just about comfort—it’s about performance, health, and personalization at scale. And behind the numbers powering that mission is CFO Nick Chammas. On this episode of Ventured Growth, Catherine Jhung sits down with Nick to discuss how Eight Sleep evolved from a niche product for athletes into a sleep fitness brand with global momentum. From raising $100M to expanding manufacturing across continents, Nick has helped steer the company through pivotal growth milestones. He shares insights into their new AI-powered sleep agent, how digital twins are driving personalized rest, and why the best product feedback comes straight from the customer. Topics include: Applying AI to sleep and biometric dataFrom product-market fit to global expansionHow Eight Sleep is solving for menopause, snoring, and temperature regulationLeading a capital-efficient team of 100Nick’s personal journey from banking to scaling a hardware brandAnd more… Nick Chammas is the CFO of Eight Sleep, the world’s first sleep fitness company. With experience across finance, operations, and strategy, he brings a holistic view to driving growth in a competitive consumer tech landscape. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! In the high-stakes world of startups, few roles have evolved more dramatically than that of the CFO. Today’s finance leader is expected to move beyond spreadsheets — shaping strategy, influencing product development, and building cross-functional trust. M.G. Thibaut has done all of that and more. In this episode, Eddie Lopez is joined by M.G. Thibaut — former CFO of Strava, DroneDeploy, and Copper, and now the founder of Coterie CFO and Executive-in-Residence at Scale Venture Partners. With roots in investment banking and big tech, M.G. has spent over 16 years helping venture-backed startups grow, scale, and stay agile through every stage. Now, she’s focused on building something new. M.G. shares the founding story of Coterie CFO, a community redefining the relationship between finance leaders and the fintech tools they rely on. She also opens up about her advisory work at Scale, the traits of high-performing finance teams, and why she believes today’s CFO must be as comfortable with ambiguity as they are with analytics. Topics Include: How M.G. pivoted from investment banking to startupsWhat makes a modern CFO indispensable to a startup’s successThe founding vision behind Coterie CFOBuilding trust and transparency with CEOs and teamsThe evolving role of the CFO in a tech-driven worldAnd other topics… M.G. Thibaut is a startup CFO turned venture partner and community builder. She is the founder of Coterie CFO and an Executive-in-Residence at Scale Venture Partners, advising startups and mentoring emerging finance leaders. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! The food delivery landscape is changing. As consumer demands grow more sophisticated, companies must innovate—balancing speed, quality, and personalization to stand out in a saturated market. But can convenience and quality coexist in this fast-paced industry? Is there a way to truly personalize the dining experience while catering to the individual needs of each customer? Kelley Morell is the CFO of Wonder, a rising "super app" for mealtime. In this episode, Hercules Capital's Ruslan Sergeyev speaks with Kelley about her career journey, transitioning from an accomplished investor at Blackstone to leading the financial strategy of this startup. She reveals the unique approach Wonder is taking to conquer the food tech space, combining a multi-faceted platform with strategic acquisitions to offer an unparalleled consumer experience. Topics Include: Wonder's evolution from mobile kitchens to a hybrid brick-and-mortar and delivery modelThe challenges of competing in a crowded market and differentiating Wonder's offeringThe role of AI in personalizing food recommendations and creating a seamless user experienceBuilding a strong team and culture to support rapid growthWonder's future plans for national expansion and a potential IPOAnd other topics… Kelley Morell is the CFO of Wonder, a rapidly growing food tech company aiming to become the "super app" for mealtime. With extensive experience in both investing and operating, Kelley provides a valuable perspective on building a successful business in a dynamic industry. Her insights into the future of food, the power of technology, and the importance of a strong team offer inspiration for anyone looking to disrupt the status quo. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! The financial services industry faces increasing pressure to combat financial crime and comply with evolving regulations. The old way of handling compliance—mostly through manual work—isn't cutting it anymore given how complex and fast-moving today's financial world is. This is where AI comes in, offering a powerful new way to strengthen compliance and protect market integrity. In this episode, Hercules Capital's Catherine Jhung speaks with Erkin Adylov, founder of Behavox and former hedge fund manager. He walks us through his career shift from managing investments to launching his own company. He explains why he started Behavox, which uses AI to help financial institutions stay compliant – a solution born from his firsthand experience seeing the limitations of traditional compliance methods. Topics Include: The rise of AI in financial services complianceHow Behavox uses AI to spot financial crimeWhy AI makes financial monitoring betterStrategies for retraining compliance teams in the age of AIBehavox’s future plans for expanding into transaction screening and policy managementAnd other topics…Erkin Adylov is the founder and CEO of Behavox, a leading provider of AI-enabled compliance solutions for the financial services industry. With a deep understanding of the complexities of financial markets and the evolving regulatory landscape, Erkin has led Behavox to become a trusted partner for institutions seeking to enhance their compliance programs and protect the integrity of capital markets. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! The biotech and pharma industries are rapidly evolving, with mergers and acquisitions driving innovation and growth. As market demands shift, these deals reshape strategies, bolster R&D, and bring groundbreaking therapies to healthcare. With over 35 years of experience, Stephen Sands has guided high-impact transactions that have shaped the biotech and pharma landscape. In this episode, Janice Bourque speaks with Stephen about his journey from bioengineer to healthcare M&A leader. They examine the forces that drive today’s major deals, from global expansion to complex valuation challenges, and the strategies that ensure success in a competitive market. Topics Include: Key trends and strategies in biotech/pharma M&AChallenges in valuing early-stage biotech companiesPharma’s evolving role in funding and scaling biotech innovationsFuture outlook for healthcare partnerships and acquisitionsStephen’s insights on the future of healthcare M&AAnd other topics…Stephen Sands is a Senior Advisor in Lazard’s Global Healthcare Group with a distinguished career in healthcare M&A. Known for his expertise in biotech and pharma, Stephen has led some of the industry's most transformative transactions, helping to drive strategic growth and innovation in the healthcare sector. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! Vijay Patel is an institutional investor turned corporate venture capitalist. He has spent the last decade at the intersection of finance and healthcare, changing the way CVS Health approaches innovation and strategic investments. His journey from traditional venture capital to leading CVS Health® Ventures has positioned him as a thought leader in corporate venture capital and healthcare innovation. In this episode, Janice Bourque is joined by Vijay Patel to discuss his path from institutional investor to Managing Partner of CVS Health Ventures. They discuss the creation and growth of CVS Ventures, highlighting Vijay's approach to fostering innovation and driving strategic value in the healthcare ecosystem. Topics Include: Vijay's transition from institutional investing to corporate venture capitalThe founding story of CVS Ventures and its impact on healthcare innovationCVS Ventures’ investment strategies and focus areasThe role of corporate venture capital in shaping the future of healthcareVijay's vision for the future of healthcare technology and innovationAnd other topics...Vijay Patel is the managing partner and co-founder of CVS Health Ventures and vice president of enterprise business development for CVS Health. Patel founded the CVS® Digital Leadership Program and has played a key role in developing strategic partnerships with digital health companies. Patel holds a bachelor's degree from the University of Pennsylvania's Jerome Fisher Program in Management and Technology and an MBA from the MIT Sloan School of Management. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! In an era where breakthrough innovations coexist with concerns over drug affordability, Peter Kolchinsky, founder and Managing Partner at healthcare and life sciences investment manager RA Capital, joins us to shed light on the factors and paths forward. Hercules Capital's Janice Bourque engages with Peter on his No Patient Left Behind initiative, a non-profit dedicated to making medicines affordable for everyone in America. Topics Include: Overview of the "No Patient Left Behind" movement and its objectivesExamining communication challenges within the drug industryThe pivotal role of insurance in enabling patient access and affordabilityStrategies to maintain support for innovation amid pricing concernsPotential solutions to bridge the gap between innovation and affordability Peter Kolchinsky, PhD is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Peter is an active investor in and board member of publicly- and privately-held companies developing drugs, medical devices, diagnostics, and research tools. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur’s Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a BA from Cornell University and a PhD in Virology from Harvard University. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! Navigating the intricate world of venture debt requires a deep understanding of both the legal landscape and financial imperatives. David Ephraim from Morrison & Foerster brings over two decades of experience to the table, making him a leading authority on structuring deals that align legal precision with business innovation. This episode, hosted by Janice Bourque from Hercules Capital, engages David Ephraim in a discussion about the nuances of venture debt, including how negotiations are framed, the roles of various stakeholders, and the essential strategies for overcoming common challenges. David also provides forward-looking insights into how the field might evolve in the coming years. Topics include: Overview of venture debt and its importanceDetailed look at negotiation processes in venture debtHow legal and business issues intertwine in these negotiationsThe importance of strategic foresight in financial planningDavid’s perspectives on the future of venture debtDavid Ephraim is the co-chair of Morrison Foerster’s Transactions Department and managing partner of their Boston office. He specializes in various aspects of secured lending, including venture debt, fund finance, and cross-border financing transactions. David's expertise ensures sophisticated solutions for banks, institutional lenders, and private funds, making him a pivotal figure in the financial industry. Join us on today’s episode, where David Ephraim’s expertise offers invaluable perspectives on the nuanced processes that underpin successful venture debt strategies, providing our listeners with guidance for navigating these essential financial instruments. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! Public market investor turned tech visionary, Casey Woo, has spent the last two decades at the forefront of technology and finance, revolutionizing the way high-growth startups approach operations and strategy. His journey from analyzing markets on Wall Street to leading Operators Guild and FOG Ventures has positioned him as a thought leader at the intersection of technology, finance, and community building. In this episode, Catherine Jhung is joined by Casey Woo to discuss his unique path from public market investor to influential COO/CFO in the tech industry. They discuss the creation and growth of Operators Guild and FOG Ventures, highlighting Casey's approach to fostering community and driving innovation in the startup ecosystem. Topics Include: -Casey's transition from public market investor to tech COO/CFO -The founding story of Operators Guild and its impact on the tech community -Inside FOG Ventures: Strategy and vision for tech startups -The role of community in the success of tech and finance ventures -Navigating high-growth challenges in the startup world -Casey's vision for the future of technology and finance -And other topics… Casey Woo is the founder of Operators Guild, the premier community and ecosystem for finance and operational professionals at high growth companies, and its associated investing arm, FOG Ventures. He has two decades of experience as a proven, serial COO/CFO in high-growth technology companies, most recently as the CFO of property tech company Landing. Casey started his career as a public market investor focused on the consumer/retail, media, industrials, technology and healthcare sectors. His expertise in blending strategic finance with operational excellence has made him a pivotal figure in shaping the landscape of technology startups. This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! In the aftermath of the 2020 biotech surge and its subsequent contraction in 2022, the biotech industry has been characterized by significant volatility. There were 21 biotechnology IPOs in 2022, a notable decrease from the record-breaking 104 IPOs in 2021. To review the highs and lows of 2023 and explore what lies ahead in 2024, distinguished biotech analyst and co-founder of Endpoints News John Carroll joins Hercules Capital's Janice Bourque. Carroll brings 45 years of award-winning journalism, and a specialization in biopharma spanning over two decades to discuss the biggest pharma deals and surprises of 2023, the impact of AI on drug development, the future of biotech in Asia, and much more.  Topics Include: The biggest pharma deals and surprises of 2023AI’s impact on drug developmentWhether or not the Inflation Reduction Act will impact pricingJohn’s major lessons from 2023The future of biotech in AsiaThe greatest concerns for the biotech industry going into 2024John’s hopes for the industry in the new yearAnd other topics… ------------------ John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Carroll has been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. Resources Mentioned: Endpoints News: https://endpts.com/  Connect with John: LinkedIn: https://www.linkedin.com/in/john-carroll-884aa410/  This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! The gaming and platform industries are dynamic sectors at the intersection of technology and entertainment, constantly evolving to meet the demands of a global audience. In 2022, the revenue from the worldwide gaming market was approximately $347 billion. Ed Lu, a seasoned executive with 23 years of financial and operational experience, has played a pivotal role in this landscape, dedicating thirteen years as the CFO at online gaming and platform companies. Ed is the current Chief Financial Officer at Fandom, the world’s largest gaming and entertainment community platform. In this episode, Hercules Capital's Lesya Kulchenko  and Ed Lu discuss Ed’s CFO experience within gaming and platform companies, top advice for new founders and aspiring CFOs in today’s business landscape, choosing between building, buying, and partnering, the key factors for successful acquisitions, when to pursue bargain opportunities, and much more. Topics Include: Ed’s top priorities as a CFO in today’s business landscapeEssential advice for emerging founders and aspiring CFOsCore values that led Ed to leadershipThe advice Ed gratefully avoidedChoosing between building, buying, and partneringKey factors for successful acquisitionsWhen companies should pursue bargain opportunitiesFactors outside of work that shape Ed as the “non-CFO CFO”And other topics…---------- Ed Lu is a seasoned executive with 23 years of financial and operational experience and thirteen years as CFO at online gaming and platform companies. He is the current Chief Financial Officer at Fandom, the world’s largest gaming and entertainment community platform. During his tenure, Fandom has grown revenue by more than 3x, acquired three companies, and doubled its employee base to 500. Before joining Fandom, Ed served as the CFO for Outpost Games and Machine Zone. His tenure at Machine Zone involved raising over $800 million in combined financings, overseeing revenue growth from $8 million to $1.7 billion, and scaling the company from 30 to 1000+ employees. In his free time, he also enjoys serving as a strategic advisor for other digital gaming companies. Resources Mentioned: “Top 10 Start-Up Tips for Founders,” by Ed Lu: https://www.linkedin.com/feed/update/urn:li:activity:6998677341623267328/  This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Share your thoughts with us! Healthcare and biotech venture capital plays a critical role in funding innovative medical technologies, drug development, and life-saving therapies. These investments drive advancements in healthcare, transforming science into products that improve global patient outcomes. Terry McGuire is a founding partner of Polaris Partners, with over 35 years of early-stage investing experience in medical and information technology companies. As a venture capitalist, Terry has invested in more than 80 companies that have raised over $7 billion in equity and corporate capital. In this episode, Hercules Capital’s Janice Bourque and Terry McGuire discuss Terry’s trajectory from generalist to distinguished expert in healthcare and biotech venture capital, strategies to find the right scientists and product, Terry’s biggest lessons in raises, limited partnerships and investor relationships, and much more. Topics Include: Terry’s path from generalist to venture capitalistStrategies to find the right scientists3 traits that can turn a scientist into an effective CEOHow to turn science into a productThe emerging technologies to look out forStrengths and weaknesses of the industryTerry’s biggest lessons from the evolution of raises, limited partnerships, and investor relationshipsAnd other topics… Terry McGuire is a founding partner of Polaris Partners, with over 35 years of early-stage investing experience in medical and information technology companies. As a venture capitalist, Terry has invested in more than 80 companies that have raised over $7 billion in equity and corporate capital. He also co-founded three companies: Inspire, AIR, and MicroCHIPS. Companies Terry has supported have touched more than 60 million patients and directly saved over 400,000 lives. Terry has been listed as one of Scientific American’s Worldview 100, Forbes’ Top Life Sciences Investors, and Forbes’ Midas 100 List of Top Tech Investors, among others. He is the chairman of the Global Venture Capital Congress, serves on several public and private boards of directors, and is the recipient of various awards, including the Albert Einstein Award for Outstanding Achievement in the Life Sciences awarded by Harvard and the City of Jerusalem.   This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.